DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer. (Q36471888)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer. |
scientific article |
Statements
DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer (English)
Yuyan Wang
Jianchun Duan
Hua Bai
Zhijie Wang
Lai Wei
Jun Zhao
Shuhang Wang
Lu Yang
Tongtong An
Meina Wu
25 September 2012
1 reference